What is the recommended treatment for an adult with pseudomembranous colitis (Clostridioides difficile infection), including first‑line therapy, management of fulminant disease, and approaches for first and subsequent recurrences?

Treatment of Pseudomembranous Colitis (Clostridioides difficile Infection)

For any initial episode of CDI, oral vancomycin 125 mg four times daily for 10 days or fidaxomicin 200 mg twice daily for 10 days is first-line therapy, regardless of disease severity. 1

Initial Episode Management

Immediate Actions

• Discontinue the inciting antibiotic immediately—this is the single most important modifiable factor to reduce recurrence and treatment failure. 1, 2
• Start empiric therapy without waiting for laboratory confirmation when clinical suspicion is high or the patient is critically ill. 2

First-Line Antibiotic Selection

Preferred regimens (equal priority):

• Fidaxomicin 200 mg orally twice daily for 10 days is preferred when cost is not limiting because it reduces recurrence by approximately 40% (13–17% vs 24–27% with vancomycin). 1, 3
• Vancomycin 125 mg orally four times daily for 10 days achieves clinical cure rates of 81–92% and is an acceptable alternative. 1, 4

Metronidazole should be avoided as first-line therapy:

• Reserve metronidazole 500 mg orally three times daily for 10 days only when vancomycin and fidaxomicin are unavailable and disease is non-severe. 5, 1
• In severe CDI, metronidazole achieves only 76% cure rates compared with 97% for vancomycin. 1
• Never use repeated metronidazole courses due to cumulative, potentially irreversible neurotoxicity. 5, 1

Severity Classification

Non-severe CDI:

• White blood cell count ≤ 15,000 cells/µL and serum creatinine < 1.5 mg/dL
• Treat with standard vancomycin or fidaxomicin dosing 5, 1

Severe CDI:

• White blood cell count ≥ 15,000 cells/µL or serum creatinine ≥ 1.5 mg/dL
• Use the same standard vancomycin 125 mg four times daily—higher doses provide no additional benefit for non-fulminant disease 1, 6

Fulminant (Life-Threatening) CDI

Fulminant disease is defined by:

• Hypotension or shock
• Ileus or colonic distension
• Toxic megacolon 5, 1

Combination regimen (all components required):

• High-dose oral vancomycin 500 mg four times daily (via mouth or nasogastric tube) 5, 1
• Plus intravenous metronidazole 500 mg every 8 hours to ensure colonic drug levels when oral delivery is compromised 5, 1
• Plus rectal vancomycin retention enema 500 mg in 100 mL normal saline every 6 hours if ileus is present 5, 1

Critical surgical considerations:

• Obtain immediate surgical consultation for total abdominal colectomy with ileostomy if perforation, refractory systemic inflammation despite antibiotics, toxic megacolon, or severe ileus develops. 1
• Operate before serum lactate exceeds 5.0 mmol/L—do not delay surgery until the patient becomes moribund. 1

First Recurrence Management

Treatment algorithm depends on initial therapy:

If initial episode was treated with metronidazole:

• Switch to vancomycin 125 mg orally four times daily for 10 days 1, 4

If initial episode was treated with standard vancomycin:

• Fidaxomicin 200 mg orally twice daily for 10 days is the preferred option, reducing second recurrence from 35.5% to 19.7%. 1, 4
• Alternative: Tapered-and-pulsed vancomycin regimen (total 6–11 weeks):
  • 125 mg four times daily for 10–14 days
  • Then 125 mg twice daily for 7 days
  • Then 125 mg once daily for 7 days
  • Then 125 mg every 2–3 days for 2–8 weeks 5, 1, 4

Rationale for taper-and-pulse approach:

• The gradual dose reduction allows gut microbiota recovery while vancomycin continues to suppress vegetative C. difficile. 1
• The pulse phase (every 2–3 days) is essential—it prevents C. difficile overgrowth during microbiota restoration. 1
• Maintain the 125 mg dose throughout; do not escalate to 500 mg, which is reserved exclusively for fulminant disease. 1, 4

Second and Subsequent Recurrences

Hierarchical treatment options:

1. Fidaxomicin 200 mg orally twice daily for 10 days (standard or extended-pulsed regimen) 1, 4

2. Continue tapered-and-pulsed vancomycin as described for first recurrence 1, 4

3. Sequential vancomycin-rifaximin therapy:

   • Vancomycin 125 mg four times daily for 10 days
   • Followed immediately by rifaximin 400 mg three times daily for 20 days (total 30 days) 1, 4

4. Fecal microbiota transplantation (FMT) is strongly recommended after at least two recurrences (i.e., three total CDI episodes) that have failed appropriate antibiotic therapy. 5, 1

   • FMT achieves 81–92% resolution rates compared with 23–40% with antibiotics alone. 1

Critical Pitfalls to Avoid

• Never use intravenous vancomycin alone for CDI—it is not excreted into the colon and has no therapeutic effect. 1
• Avoid antiperistaltic agents (loperamide, diphenoxylate) and opioid analgesics in all CDI patients—they worsen outcomes and increase complications. 1, 2
• Do not perform a "test of cure" after completing therapy; clinical improvement within 3–5 days is the appropriate endpoint. 1, 2
• Do not use high-dose vancomycin (500 mg four times daily) for non-fulminant disease—the standard 125 mg dose already exceeds the MIC₉₀ for C. difficile by several orders of magnitude. 1, 6
• Failing to discontinue the inciting antibiotic dramatically increases recurrence risk—this is the most common preventable cause of treatment failure. 1, 2

Treatment Monitoring

• Expect clinical response within 3–5 days after starting appropriate therapy. 1, 2
• Approximately 20% of patients experience recurrence after initial treatment, with higher risk in elderly patients, those with continued antibiotic use, and those with multiple comorbidities. 1, 2
• Discontinue unnecessary proton pump inhibitors when feasible, though insufficient evidence exists to mandate cessation solely for CDI prevention. 5, 1